In Oct 2007, the FDA introduced which the labeling for all PDE5 inhibitors, like tadalafil, needs a far more distinguished warning on the potential hazard of unexpected Listening to decline as the result of publish-promoting stories of short-term deafness related to use of PDE5 inhibitors.[19] Di